BillionToOne

BillionToOne

Molecular diagnostics for prenatal and oncology testing

About BillionToOne

Simplify's Rating
Why BillionToOne is rated
A-
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A on Differentiation

Industries

Biotechnology

Healthcare

Company Size

501-1,000

Company Stage

Series D

Total Funding

$425.9M

Headquarters

Menlo Park, California

Founded

2016

Overview

BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases at a single base-pair resolution, enabling the identification of minute variations in DNA. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which monitors the effectiveness of that therapy. Unlike many competitors, BillionToOne emphasizes accuracy, efficiency, and accessibility in molecular testing, providing diagnostic services directly to healthcare providers. Their goal is to positively impact healthcare by making advanced molecular testing available to all, supported by a team of dedicated engineers and scientists.

YC Company
Simplify Jobs

Simplify's Take

What believers are saying

  • BillionToOne achieved 100% accuracy in non-invasive fetal RhD detection in diverse US populations.
  • The company reported over 100% year-over-year revenue growth in 2024.
  • BillionToOne's expansion into Austin, Texas, will create 1,000 new jobs.

What critics are saying

  • Emerging competition in liquid biopsy could impact BillionToOne's market share.
  • Continuous R&D investment is needed to keep up with rapid technological advancements.
  • Dependence on UNITY test poses a risk if market demand shifts.

What makes BillionToOne unique

  • BillionToOne's QCT technology offers single-molecule precision in DNA counting.
  • UNITY test is the only non-invasive prenatal screen for recessive conditions without a male sample.
  • Their oncology tests provide precise tumor burden measurement using liquid biopsy technology.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$425.9M

Above

Industry Average

Funded Over

6 Rounds

Notable Investors:
Series D funding is typically for companies that are already well-established but need more funding to continue their growth. This round is often used to stabilize the company or prepare for an IPO.
Series D Funding Comparison
Above Average

Industry standards

$77M
$70M
Twilio
$80M
Handshake
$100M
Affirm
$130M
BillionToOne

Benefits

Competitive pay

Retirement savings package

Parental leave

Free snacks & lunches

Medical, dental, & vision premiums

On campus perks

Free-on-site EV charging

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
PR Newswire
Apr 25th, 2025
Billiontoone To Present New Data At Aacr Annual Meeting 2025

Innovations in liquid biopsy technology demonstrate a more accurate method to infer in-tissue copy number from ctDNA, detection of a novel non-tumor derived pseudogene of GNA11, and development of an epigenetic-based method for precise tumor burden measurementMENLO PARK, Calif., April 25, 2025 /PRNewswire/ -- BillionToOne , a molecular diagnostics company with a mission to create powerful and accurate tests accessible to all, announced today several abstract presentations that will be showcased at the American Association of Cancer Research (AACR) Annual Meeting on April 25–30, 2025, in Chicago, IL.Each abstract highlights BillionToOne's relentless focus in advancing the field of liquid biopsy technology:Title: "Tumor fraction estimation and tissue copy number inference using copy number signal from a liquid biopsy assay"Session Time: 4/29/25 at 9:00 AM - 12:00 PMLocation: Poster Section 20Title: "Detection of a novel GNA11 processed pseudogene from cfDNA and implications for liquid biopsy"Session Time: 4/29/25 at 2:00 - 5:00 PMLocation: Poster Section 31Title: "Circulating cell-free methylated tumor DNA measurements correlate with plasma VAF-based tumor fraction estimates"Session Time: 4/29/25 at 2:00 - 5:00 PMLocation: Poster Section 32"These data presented at AACR represent our dedication in advancing liquid biopsy testing with our proprietary single molecule precision technology and setting new standards in what can be achieved with plasma-based tests," said Dr. Gary Palmer, Chief Medical Officer, Oncology at BillionToOne. "Together, these innovations enhance the accuracy and robustness of ctDNA-based cancer profiling and monitoring, which will ultimately enable more precise treatment decisions for patients."About BillionToOneHeadquartered in Menlo Park, California, BillionToOne is a precision diagnostics company on a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's single-molecule NGS (smNGS) platform, which includes the patented Quantitative Counting Template (QCT) technology, is the only multiplex methodology that can accurately count DNA molecules at the single-molecule level. For more information, please visit www.billiontoone.com .Media Contact: [email protected]SOURCE BillionToOne

Trade Show News
Apr 25th, 2025
BillionToOne to Present New Data at AACR Annual Meeting 2025

BillionToOne to present new data at AACR Annual Meeting 2025.

PR Newswire
Mar 18th, 2025
Billiontoone Celebrates Major Milestone: 1 Million Unity Tests

UNITY is the only commercially available non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a single maternal blood draw.MENLO PARK, Calif., March 18, 2025 /PRNewswire/ -- BillionToOne, Inc. , a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, has reached a significant milestone of conducting one million UNITY prenatal tests. This achievement highlights the company's exceptional execution and superior product differentiation, which has fueled remarkable year-over-year growth and established BillionToOne as a leading player in the U.S. prenatal testing market.Powered by BillionToOne's patented Quantitative Counting Template™ (QCT™) molecular counting technology, the UNITY Fetal Risk Screen™ stands apart as the only prenatal genetic test that directly assesses a baby's risk for recessively inherited conditions, including cystic fibrosis, spinal muscular atrophy (SMA), and sickle cell disease, without requiring a male partner's sample or invasive testing."Surpassing 1 million UNITY tests in only 5 years is not just a milestone for our company, but a testament to how our technology is transforming prenatal care," said Oguzhan Atay, Ph.D., Co-Founder and CEO of BillionToOne. "What is more impressive is that our annual run-rate is already above 500,000 UNITY tests this year, indicating truly exponential growth and establishment of UNITY as the next standard in prenatal care. This achievement would not be possible without the dedication of our employees, the support of our partners, and the trust of our healthcare providers."BillionToOne has firmly established itself as the fastest-growing molecular diagnostics laboratory, with 100% year-over-year revenue growth in 2024.This milestone further solidifies BillionToOne's position as a leading provider in democratizing access to essential prenatal testing, particularly for those who need it most

PR Newswire
Feb 27th, 2025
Billiontoone'S Pioneering Study Demonstrates 100% Accuracy For Non-Invasive Fetal Rhd Detection In Us Population

Peer reviewed research published in Green Journal shows BillionToOne's NGS technology excels in testing diverse US populationsMENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ -- BillionToOne , a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announced today the groundbreaking results from a recent large US-based clinical study demonstrating 100% accuracy in its non-invasive prenatal test (NIPT) for fetal RhD status. This is BillionToOne's third peer reviewed study of its fetal antigen assay, and the second published in The Journal of Obstetrics and Gynecology, the official journal of the American College of Obstetricians and Gynecologists (ACOG), also known as "The Green Journal," which showcases the accuracy and clinical validity of BillionToOne's fetal RhD NIPT.Approximately 15% of pregnant individuals in the US are RhD-negative. However, in ~40% of these pregnancies, the fetus is also RhD-negative, making RhoGAM administration unnecessary. To date, BillionToOne has conducted RhD testing on 469 participants through clinical validation studies, while providing over 150,000 commercial RhD tests to patients nationwide.This study demonstrates that BillionToOne's proprietary next-generation sequencing (NGS) with Quantitative Counting Template™ (QCT™) technology provides conclusive results with 100% accuracy. BillionToOne's study included all samples, including difficult to identify variants such as RHDѰ and RHD-C-DE, which are often excluded in other studies; therefore, it reflected true clinical performance

PR Newswire
Jan 28th, 2025
Billiontoone Reports Over 100% Growth In Revenue Year-Over-Year

Company Announces Record Financial Results at 43rd Annual J.P. Morgan Healthcare ConferenceMENLO PARK, Calif., Jan. 28, 2025 /PRNewswire/ -- BillionToOne , a next-generation molecular diagnostics company, announced record financial results at this year's J.P. Morgan Healthcare Conference in San Francisco. In 2024, the company's revenue reached $153 million, more than doubling from $72 million in 2023.BillionToOne's success has been driven primarily by its prenatal testing business, which has captured an estimated 15% market share in the U.S."We saw strong momentum in our prenatal business during 2024, with tremendous revenue growth and profitability in the fourth quarter," said Dr. Oguzhan Atay, Co-founder and CEO of BillionToOne

Recently Posted Jobs

Sign up to get curated job recommendations

Senior Automation Associate - Oncology

$83.2k - $93.6k/yr

Menlo Park, CA, USA

Oncology Specialist

$155.9k - $171.5k/yr

Fort Worth, TX, USA

Quality Engineer - Oncology

$119.6k - $130.1k/yr

Menlo Park, CA, USA

See All Jobs

BillionToOne is Hiring for 59 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update BillionToOne's jobs every few hours, so check again soon! Browse all jobs →

Oncology Specialist

$155.9k - $171.5k/yr

Fort Worth, TX, USA

Quality Engineer - Oncology

$119.6k - $130.1k/yr

Menlo Park, CA, USA

See All Jobs

BillionToOne is Hiring for 59 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update BillionToOne's jobs every few hours, so check again soon! Browse all jobs →